Globus Medical, Inc.

NYSE:GMED Stock Report

Market Cap: US$11.3b

Globus Medical Future Growth

Future criteria checks 3/6

Globus Medical is forecast to grow earnings and revenue by 49.5% and 6.3% per annum respectively. EPS is expected to grow by 48.1% per annum. Return on equity is forecast to be 10.8% in 3 years.

Key information

49.5%

Earnings growth rate

48.1%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate6.3%
Future return on equity10.8%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

Globus Medical Stock: Re-Rated After A Solid Year

Nov 18

Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet

Nov 04
Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet

Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit

Oct 14
Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit

Globus Medical: A Post Acquisition Analysis

Aug 26

Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

Jun 28
Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Apr 08
An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Mar 20
Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

Feb 27

Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Feb 09
Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Jan 17
Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Globus Medical: Merger Overhang Lingering

Nov 27

Globus Medical: Almost Having My Back

Sep 13

Globus Medical: Slightly Too Pricey Right Now

Aug 07

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

Jul 18

Globus Medical Q4 2022 Earnings Preview

Feb 20

Globus Medical: An Impressive Long-Term Revenue Growth Play

Jan 08

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line

Nov 08

Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact

Sep 02

Earnings and Revenue Growth Forecasts

NYSE:GMED - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,845467N/AN/A12
12/31/20252,664404593N/A14
12/31/20242,497140458N/A14
9/30/20242,47992294415N/A
6/30/20242,23741161262N/A
3/31/20241,89867152243N/A
12/31/20231,568123165243N/A
9/30/20231,226158129203N/A
6/30/20231,097204121185N/A
3/31/20231,069201117187N/A
12/31/20221,023190104178N/A
9/30/2022998155118191N/A
6/30/2022974155157235N/A
3/31/2022961142194257N/A
12/31/2021958149219276N/A
9/30/2021942187226280N/A
6/30/2021928184203256N/A
3/31/2021826122165220N/A
12/31/2020789102135199N/A
9/30/202076795108173N/A
6/30/202074789115176N/A
3/31/2020793148110175N/A
12/31/2019785155101172N/A
9/30/201977014690162N/A
6/30/201974314382158N/A
3/31/201972215093169N/A
12/31/2018713156122182N/A
9/30/2018693144126182N/A
6/30/2018676134N/A165N/A
3/31/2018655118N/A158N/A
12/31/2017636107N/A159N/A
9/30/2017612107N/A166N/A
6/30/2017595108N/A174N/A
3/31/2017581105N/A171N/A
12/31/2016564104N/A148N/A
9/30/2016553118N/A166N/A
6/30/2016554118N/A153N/A
3/31/2016548116N/A143N/A
12/31/2015537113N/A124N/A
9/30/2015518103N/A80N/A
6/30/201549999N/A85N/A
3/31/201548196N/A85N/A
12/31/201446792N/A79N/A
9/30/201445486N/A110N/A
6/30/201444383N/A108N/A
3/31/201443670N/A104N/A
12/31/201342769N/A93N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMED's forecast earnings growth (49.5% per year) is above the savings rate (2.6%).

Earnings vs Market: GMED's earnings (49.5% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: GMED's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GMED's revenue (6.3% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: GMED's revenue (6.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GMED's Return on Equity is forecast to be low in 3 years time (10.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Globus Medical, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason WittesAegis Capital Corporation
Ishan MajumdarBaptista Research
Matt MiksicBarclays